Anaplu Powder for Suspension 6mg/mL (Oseltamivir Phosphate)

Adult dose

Influenza A and influenza B virus infections: Initiate treatment on the first or second day after the onset of influenza symptoms. This medication may be administered regardless of food intake, and tolerability may improve in some patients when taken with food. Adults and adolescents 13 years of age or older: Administer 75 mg of oseltamivir orally twice daily for 5 days. Adults and adolescents 13 years of age or older who have difficulty swallowing capsules should use this medication. Patients with renal impairment (treatment): No dose adjustment is required in patients with creatinine clearance of 60 mL/min or greater. A reduced dose of 30 mg twice daily for 5 days is recommended for patients with creatinine clearance of 30 ~ 60 mL/min. A reduced dose of 30 mg once daily for 5 days is recommended for patients with creatinine clearance of 10 ~ 30 mL/min. Patients receiving periodic hemodialysis should receive a 30mg dose of this medication after each dialysis session to maintain therapeutic plasma concentrations, and the treatment period should not exceed 5 days. If influenza symptoms develop during the 48 hours between dialysis sessions, the dose may be administered before the start of dialysis. For peritoneal dialysis, a single 30mg dose of this medication after dialysis is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. No dose adjustment is required for treatment in adults with mild to moderate hepatic impairment (Child-Pugh score ≤ 9). Prevention of influenza A and influenza B virus infections Adults and adolescents 13 years of age or older: For close contacts of an infected person, administer 75 mg of oseltamivir orally once daily for 10 days. Begin administration within 2 days of contact with the infected person. The recommended dose for prevention during an influenza outbreak is 75 mg once daily. The safety and efficacy of this medication have been demonstrated for up to 6 weeks. The preventive effect continues while the medication is being taken. Patients with renal impairment (prevention): No dose adjustment is required in patients with creatinine clearance of 60 mL/min or greater. A reduced dose of 30 mg once daily is recommended for patients with creatinine clearance of 30 ～ 60 mL/min. A reduced dose of 30 mg once every other day is recommended for patients with creatinine clearance of 10 ～ 30 mL/min. Patients receiving periodic hemodialysis should receive a 30mg dose of this medication after every 2 dialysis sessions to maintain therapeutic plasma concentrations. The initial dose may be administered before the start of dialysis. For peritoneal dialysis, administration of 30mg of this medication after dialysis once weekly is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. No dose adjustment is required for prevention in adults with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

Child dose

Children 1 to 12 years of age (treatment), body weight ≤ 15 kg: 30 mg per dose twice daily; suspension (6mg/mL) 5.0 mL per dose twice daily Children 1 to 12 years of age (treatment), body weight 15 kg<, ≤ 23 kg: 45 mg per dose twice daily; suspension (6mg/mL) 7.5 mL per dose twice daily Children 1 to 12 years of age (treatment), body weight 23 kg<, ≤ 40 kg: 60 mg per dose twice daily; suspension (6mg/mL) 10.0 mL per dose twice daily Children 1 to 12 years of age (treatment), body weight > 40 kg: 75 mg per dose twice daily; suspension (6mg/mL) 12.5 mL per dose twice daily Pediatric patients weighing more than 40 kg: If they can swallow capsules, they may take a 75mg capsule twice daily or a 30mg capsule and a 45mg capsule twice daily instead of the recommended dose of this medication. Infants 2 weeks to less than 1 year of age (infants 2 weeks to 12 months): Administer 3mg/kg of this medication orally twice daily for 5 days. This does not apply to infants with a postconceptional age of less than 36 weeks. Infants 2 weeks to less than 1 year of age, body weight 3 kg: 9 mg per dose twice daily; suspension (6mg/mL) 1.5 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 4 kg: 12 mg per dose twice daily; suspension (6mg/mL) 2.0 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 5 kg: 15 mg per dose twice daily; suspension (6mg/mL) 2.5 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 6 kg: 18 mg per dose twice daily; suspension (6mg/mL) 3.0 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 7 kg: 21 mg per dose twice daily; suspension (6mg/mL) 3.5 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 8 kg: 24 mg per dose twice daily; suspension (6mg/mL) 4.0 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 9 kg: 27 mg per dose twice daily; suspension (6mg/mL) 4.5 mL per dose twice daily Infants 2 weeks to less than 1 year of age, body weight 10 kg: 30 mg per dose twice daily; suspension (6mg/mL) 5.0 mL per dose twice daily Infants less than 1 year of age: A dose of 3mg/kg of this medication is recommended. Children 1 to 12 years of age (prevention), body weight ≤ 15 kg: 30 mg per dose once daily; suspension (6mg/mL) 5.0 mL per dose once daily Children 1 to 12 years of age (prevention), body weight 15 kg<, ≤ 23 kg: 45 mg per dose once daily; suspension (6mg/mL) 7.5 mL per dose once daily Children 1 to 12 years of age (prevention), body weight 23 kg<, ≤ 40 kg: 60 mg per dose once daily; suspension (6mg/mL) 10.0 mL per dose once daily Children 1 to 12 years of age (prevention), body weight > 40 kg: 75 mg per dose once daily; suspension (6mg/mL) 12.5 mL per dose once daily Pediatric patients weighing more than 40 kg: If they can swallow capsules, they may take a 75mg capsule once daily or a 30mg capsule and a 45mg capsule once daily for 10 days instead of the recommended dose of this medication. The safety and efficacy of prevention of influenza A and B virus infections in infants less than 1 year of age have not been evaluated.

This medication is used to treat or prevent influenza virus infections, but it cannot replace influenza vaccination. This medication is only effective against influenza A and B, and its safety and efficacy have not been established for other infections. Particularly in children and adolescents, there may be rare occurrences of abnormal behavior or neurological adverse reactions, so caregivers should observe for unusual behaviors after administration. Patients with allergies to this drug or its components should not take it. Patients with impaired kidney function or those undergoing hemodialysis need dosage adjustments, and it is not recommended for patients with end-stage renal failure. High-risk patients, such as those with asthma, chronic bronchitis, and immunosuppressed individuals, should use this drug with caution. Common side effects may include nausea, vomiting, headache, and these symptoms are usually transient. Rarely, anaphylaxis, liver dysfunction, skin rashes, acute renal failure, and neurological symptoms may occur, so report any unusual symptoms to healthcare professionals immediately. This medication contains sorbitol, so patients with hereditary fructose intolerance should avoid it. While interactions with other medications are unlikely, caution is advised when used in conjunction with specific medications. Women who are pregnant or breastfeeding should consult a doctor about the use of this drug, and it should only be used when the therapeutic benefits outweigh the risks. Safety and efficacy for infants under 1 year have not been established, so it is advisable not to use this drug in this age group. Elderly patients should be closely monitored considering physical function decline and pre-existing conditions. Adhere to the prescribed dosage and administration and take missed doses as soon as possible but not too close to the next scheduled dose. This drug is most effective when used at the onset of influenza symptoms. If unusual behavior or severe side effects occur after taking it, discontinue use and consult a healthcare provider. Store this medication out of the reach of children and follow the storage period after preparation.

• nausea
• vomiting
• headache
• pain
• unstable angina
• anemia
• pseudomembranous colitis
• pneumonia
• peritonsillar abscess
• humeral fracture

Store this medication in a tightly sealed container to prevent air or moisture ingress and keep it at room temperature between 1 and 30 degrees Celsius. Proper storage maintains the drug's effectiveness and prevents deterioration.

Appearance

White or pale yellow granules contained in a brown glass bottle for reconstitution

Package unit

10g/bottle (50mL)